Sleep & Recovery Stack: DSIP + Pinealon + BPC-157
Last updated: 2026-03-03
The Sleep & Recovery Stack combines three peptides — DSIP, Pinealon, and BPC-157 — into a protocol designed to improve sleep architecture, support circadian rhythm regulation, and accelerate overnight tissue repair. Poor sleep quality undermines every recovery process in the body, making this stack relevant for athletes, shift workers, and anyone struggling with non-restorative sleep.
DSIP (Delta Sleep-Inducing Peptide) is an endogenous nonapeptide first isolated from cerebral venous blood during slow-wave sleep. Pinealon is a short bioregulatory peptide (Glu-Asp-Arg) that acts on pinealocytes to support melatonin synthesis and circadian entrainment. BPC-157 contributes its well-documented cytoprotective and tissue repair properties, which are amplified during the deep sleep phases that DSIP and Pinealon promote.[1]
This guide covers the complete protocol including dosage schedules, synergy rationale, cycling advice, safety considerations, and research citations. All information is presented for educational purposes and should not be interpreted as medical advice.
Compounds in This Stack
DSIP (Delta Sleep-Inducing Peptide)
Slow-wave sleep induction, stress hormone modulation, sleep architecture improvement
DSIP is a naturally occurring nonapeptide (Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu) discovered in 1977 from the cerebral venous blood of rabbits during electrically induced sleep. It crosses the blood-brain barrier and modulates sleep-wake cycles by promoting delta-wave (slow-wave) sleep — the most restorative phase of the sleep cycle.[1]
Mechanism in this stack: DSIP acts on multiple neuroendocrine pathways: it modulates cortisol and ACTH secretion to reduce stress-mediated sleep disruption, influences serotonin and dopamine turnover in key sleep-regulating brain regions, and promotes the delta EEG pattern associated with deep restorative sleep. It serves as the primary sleep-enhancing agent in this stack.
| Parameter | Detail |
|---|---|
| Research Dosage | 100–300 mcg per evening |
| Route | Subcutaneous or intranasal |
| Frequency | Once daily, 30–60 minutes before bed |
| Half-Life | ~15–25 minutes (rapid central uptake) |
| Onset | Effects typically noticed within 20–40 minutes |
Pinealon
Circadian rhythm regulation, melatonin synthesis support, neuroprotection
Pinealon (Glu-Asp-Arg) is a synthetic tripeptide bioregulator developed by the Khavinson research group at the Saint Petersburg Institute of Bioregulation and Gerontology. It belongs to the cytomax class of short peptides that target specific cell types — in Pinealon's case, pinealocytes in the pineal gland.[2]
Mechanism in this stack: Pinealon penetrates cell membranes and interacts with DNA in pinealocytes to upregulate genes involved in melatonin biosynthesis. By supporting endogenous melatonin production rather than introducing exogenous melatonin, Pinealon helps restore natural circadian signaling without suppressing the body's own melatonin pathways. It complements DSIP by addressing the circadian timing component of sleep.
| Parameter | Detail |
|---|---|
| Research Dosage | 10 mg per day (oral capsule) |
| Route | Oral or sublingual |
| Frequency | Once daily, 1–2 hours before bed |
| Half-Life | Short (tripeptide rapidly absorbed) |
| Cycle Pattern | 10–20 days on, 10 days off |
BPC-157
Overnight tissue repair, gut healing, cytoprotection
BPC-157 (Body Protection Compound-157) is a synthetic pentadecapeptide derived from a protective protein found in human gastric juice. In this stack it serves as the tissue repair component, leveraging the enhanced recovery window created by improved sleep quality.[3]
Mechanism in this stack: Deep slow-wave sleep (promoted by DSIP) is when the body releases the highest concentrations of growth hormone and activates tissue repair pathways. BPC-157 amplifies these repair processes by upregulating VEGF for angiogenesis, modulating the nitric oxide system, and activating the EGR-1 pathway for collagen remodeling. Administering BPC-157 before bed synchronizes its peak activity with the body's natural repair window.
| Parameter | Detail |
|---|---|
| Research Dosage | 250–500 mcg per evening |
| Route | Subcutaneous (near injury site if applicable) |
| Frequency | Once daily, at bedtime |
| Oral Option | 500–1000 mcg for gut-focused recovery |
| Half-Life | ~4–6 hours |
How They Work Together
The Sleep & Recovery Stack creates a three-layer synergy: DSIP induces the deep sleep state, Pinealon optimizes circadian timing, and BPC-157 maximizes the tissue repair that occurs during those enhanced sleep phases. Each peptide addresses a different bottleneck in the sleep-recovery axis.
Layer 1: Deep Sleep Induction (DSIP)
DSIP directly promotes delta-wave sleep patterns by modulating GABAergic and serotonergic signaling in the hypothalamus and brainstem sleep centers. It reduces cortisol and ACTH secretion, removing a primary barrier to deep sleep — especially relevant for individuals with stress-driven insomnia or HPA axis dysregulation. By increasing the percentage of time spent in slow-wave sleep, DSIP extends the window during which the body releases growth hormone and activates repair cascades.[1]
Layer 2: Circadian Optimization (Pinealon)
Even with improved sleep depth, poor circadian timing undermines recovery. Pinealon supports endogenous melatonin production by acting directly on pinealocyte gene expression, helping anchor the sleep-wake cycle to appropriate timing. Unlike exogenous melatonin — which can suppress endogenous production with chronic use — Pinealon supports the body's own melatonin synthesis machinery. This is particularly valuable for shift workers, jet-lagged travelers, or anyone with disrupted light-dark exposure patterns.[2]
Layer 3: Repair Amplification (BPC-157)
BPC-157's tissue repair mechanisms — angiogenesis via VEGF, collagen remodeling via EGR-1, and cytoprotection via NO modulation — are most effective when the body is already in a repair-permissive state. Deep sleep provides exactly that state, with elevated growth hormone, reduced cortisol, and increased parasympathetic tone. Administering BPC-157 at bedtime synchronizes its pharmacological activity with the body's endogenous repair window, potentially amplifying outcomes beyond what daytime administration achieves.[3]
The Combined Effect
Users of this stack commonly report not just better sleep but better recovery from sleep: waking with less stiffness, reduced morning pain at injury sites, and improved next-day energy. The mechanism is straightforward — better sleep quality drives better repair, and BPC-157 provides the molecular tools to capitalize on that improved repair window. For athletes or anyone managing chronic injuries, the sleep-recovery connection makes this a uniquely practical stack.
Researching peptides? We did the hard part.
Get our free Peptide Starter Kit — the 5 most researched compounds, simplified into one actionable guide.
Protocol & Dosage Schedule
Dosage Schedule
| Phase | DSIP | Pinealon | BPC-157 | Duration |
|---|---|---|---|---|
| Introduction | 100 mcg before bed | 10 mg oral, evening | 250 mcg SubQ at bed | Weeks 1–2 |
| Active Phase | 200–300 mcg before bed | 10 mg oral, evening | 250–500 mcg SubQ at bed | Weeks 3–6 |
| Taper / Maintenance | 100 mcg 3–4x/week | 10 mg oral, as needed | 250 mcg SubQ as needed | Weeks 7–8 |
Cycle Length
6–8 weeks active use. DSIP should be cycled to prevent tolerance — 6 weeks on, 2–4 weeks off is a common pattern. Pinealon follows a bioregulator cycling pattern of 10–20 days on, 10 days off. BPC-157 can continue independently if tissue repair needs persist. A minimum 3-week break from the full stack is recommended between cycles.
Timing & Administration
Evening protocol (all three compounds): Administer the entire stack within a 1–2 hour window before bed. A typical timing sequence:
- 2 hours before bed: Pinealon 10 mg oral or sublingual — allows time for circadian signaling to begin
- 30–60 minutes before bed: DSIP 100–300 mcg subcutaneous (abdominal) — onset within 20–40 minutes
- At bedtime: BPC-157 250–500 mcg subcutaneous (near injury site or abdominal) — active during peak deep sleep
Sleep hygiene matters: This stack works best when combined with basic sleep hygiene: consistent sleep-wake times, cool dark bedroom (65–68°F), no screens 1 hour before bed, and no caffeine after 2 PM. The peptides support sleep physiology but cannot override consistently poor sleep habits.
What to Expect
Individual responses vary based on baseline sleep quality, stress levels, injury status, and other factors. The following timeline reflects commonly reported observations.
| Timeframe | Expected Observations |
|---|---|
| Days 1–3 | Faster sleep onset, vivid dreams (common with DSIP), subjective sense of deeper sleep. Some users report morning grogginess during initial adjustment. |
| Week 1 | Improved sleep continuity (fewer nighttime awakenings). Reduced morning stiffness at injury sites. Early circadian rhythm stabilization from Pinealon. |
| Weeks 2–3 | Noticeable improvement in next-day energy and recovery. Athletes report improved training readiness. Sleep tracking data (if used) typically shows increased deep sleep percentage. |
| Weeks 4–6 | Peak benefits: consistent sleep architecture improvement, meaningful tissue repair progress from BPC-157, stable circadian rhythm. Most users feel the full synergy of the stack at this point. |
| Weeks 7–8 (Taper) | Gradual dose reduction of DSIP. Many users retain improved sleep patterns for weeks after discontinuation, suggesting a "resetting" effect on sleep architecture. |
Safety & Contraindications
Known Side Effects
All three peptides in this stack have favorable safety profiles in available research, though long-term human clinical trial data is limited.
DSIP reported side effects:
- Morning grogginess during the first 2–3 days (usually resolves with dose adjustment)
- Vivid or unusual dreams
- Mild headache (infrequent)
- Injection site irritation
Pinealon reported side effects:
- Generally very well tolerated as an oral tripeptide
- Mild drowsiness (intended effect; administer in the evening only)
- Rare gastrointestinal discomfort
BPC-157 reported side effects:
- Mild nausea (particularly with oral administration)
- Injection site redness or bruising
- Dizziness (rare)
Contraindications and Cautions
- Sedative medications: DSIP has central nervous system effects. Do not combine with benzodiazepines, Z-drugs (zolpidem/zaleplon), opioids, or other CNS depressants without medical supervision.
- Cancer history: BPC-157 promotes angiogenesis. Individuals with cancer history should avoid this stack. This is a theoretical concern, not confirmed in studies.
- Pregnancy and breastfeeding: No safety data for any of these peptides during pregnancy or lactation. Avoid entirely.
- Alcohol: Avoid alcohol on the same evening as DSIP administration, as both have CNS-depressant effects.
- Depression or mood disorders: DSIP modulates serotonin and dopamine pathways. Those on SSRIs, SNRIs, or MAOIs should consult a healthcare provider before using this stack.
Quality and Sourcing
DSIP is a relatively fragile peptide that requires careful handling. Verify third-party purity testing (HPLC, 98%+ purity) and proper cold-chain shipping. Pinealon as an oral tripeptide is more stable but should come from a reputable bioregulator supplier. BPC-157 quality varies significantly — always request a certificate of analysis (COA).
Important: None of these peptides is FDA-approved for human use. This information is for educational purposes only. Always consult a qualified healthcare professional before beginning any peptide protocol.
Where to Buy These Peptides
Third-party tested, research-grade peptides from our trusted supplier. Use code PEPTIDESINSIDER for 15% off.
Frequently Asked Questions
References
- Graf MV, Kastin AJ. Delta sleep-inducing peptide (DSIP): a review. Neuroscience & Biobehavioral Reviews, 1984.
- Khavinson VKh, Linkova NS, Tarnovskaya SI. Short peptides regulate gene expression. Bulletin of Experimental Biology and Medicine, 2016.
- Sikiric P, Seiwerth S, Rucman R, et al.. Stable gastric pentadecapeptide BPC 157: novel therapy in gastrointestinal tract. Current Pharmaceutical Design, 2011.
Researching peptides? We did the hard part.
Get our free Peptide Starter Kit — the 5 most researched compounds, simplified into one actionable guide.
Related Stacks
Individual Compound Guides
Peptides Insider Editorial Team
Our content is reviewed for accuracy and grounded in peer-reviewed research where available. We do not provide medical advice. Always consult a qualified healthcare professional.